# Long-Term Carbohydrate-Containing Late-Evening Snack Significantly Improves the Ratio of Branched Chain Amino Acids to Aromatic Amino Acids in Adults with Liver Cirrhosis due to Hepatitis B

Authors: Wei Hou; Zheng Lv; Jing Yang; Jing Wu; Zhong-ying Wang; Qing-hua Meng
Journal: BioMed Research International
 (2021)

---

## Abstract

Background. The liver is the primary organ for amino acid metabolism, and metabolic disorder of amino acids is common in liver disease. However, the characteristics of plasma amino acid profiles in patients with HBV-related cirrhosis and the impacts of late-evening snack (LES) on cirrhosis are unclear. Objectives. To investigate the characteristics of plasma amino acid profiles in patients with HBV-related chronic hepatitis, cirrhosis, and the effects of late-evening snacks on plasma amino acid profiles. Methods. 86 patients with HBV-related cirrhosis and eighty patients with chronic hepatitis B were included in this study. The plasma amino acid profiles were measured by the amino acid analyzer. Patients were randomly divided into two groups, of which the liver cirrhosis group was to receive daily LES (n=43) or non-LES (n=43) for 6 months. Plasma amino acid profiles and biochemical parameters were measured in both groups at baseline and after 1, 3, and 6 months. Results. Compared to healthy controls, the plasma concentration in the liver cirrhosis group of threonine, serine, glycine, glutamine, cysteine, tyrosine, phenylalanine, arginine, and methionine increased significantly (P<0.05), while the ratio of branched chain amino acids (BCAA) to aromatic amino acids (AAA) decreased significantly (P<0.05). A carbohydrate-predominant LES treatment resulted in a significant increase in BCAA/AAA and decrease in the level of ammonia and glutamine compared with baseline after 6 months of supplementation (P<0.05). Patients with Child-Pugh B and C are more responsive to changes in amino acid profiles than those with Child-Pugh A. Conclusions. The application of an LES carbohydrate module for six months in liver cirrhosis patients was associated with increased BCAA/AAA and decreased level of ammonia. Patients with Child-Pugh B and C grades were the most beneficial population.


---

## Body

## 1. Introduction

Liver cirrhosis is the result of chronic liver injury caused by various etiologies. According to the World Health Organization in July 2015, more than 240 million people worldwide are chronically infected with hepatitis B, amid which 20%-30% develop cirrhosis or liver cancer, and more than 780,000 annual deaths due to hepatitis B-related cirrhosis and liver cancer [1]. Protein-energy malnutrition is one of the most common comorbidities related to cirrhosis in adults, which is characterized by increased fat and protein oxidation and decreased carbohydrate utilization in the fasted state [2–4]. Protein wasting is the most typical feature of the alterations in nutrient utilization, which is manifested with muscle mass loss, hypoalbuminemia, and abnormal amino acid profile [5–8].The normal metabolism of amino acids is an important basis for life activities, and it plays an indispensable role in various fundamental biological processes. The changes of plasma amino acid profiles were also associated with the severity of liver injury. The use of BCAA as a nutritional supplementation may contribute to the positive effects of LES on survival in patients with cirrhosis. We, therefore, compared the survival rates between patients treated with LES and those given daytime BCAA supplementation and found that LES supplementation, compared to daytime supplementation, clearly improves prognosis in patients with cirrhosis. The characteristics were that aromatic amino acids (AAA; phenylalanine, tyrosine, and tryptophan) increased, branched chain amino acids (BCAA; valine, leucine, and isoleucine) decreased, and the ratio of BCAA to AAA decreased [9]. Apart from perturbations in BCAA and AAA levels, changes in plasma concentrations of other amino acids were also observed in previous studies.Current guidelines from both the American Society for Parenteral and Enteral Nutrition [10] and the European Society for Clinical Nutrition and Metabolism recommend nutritional support through night time for energy requirement and thus further preventing the increased utilization of lean body stores because of overnight fasting in cirrhotic patients. Late-evening snacks (LES) containing multiple nutrients, usually rich in BCAA and/or carbohydrates, are reported to be beneficial not only in reducing the oxidation of fat and nitrogen for energy supplementation in the fasted state but also in maintaining overall nitrogen balance and improving these patients’ quality of life [11–13]. An LES has been shown to improve the nutritional status, liver function reserves, and sarcopenia in patients with cirrhosis, each of which raises the potential to improve the survival of these patients; however, little is known about the survival benefit of LES thus far. To date, few studies have investigated the impact of an LES on amino acid profiles especially the ratio of BCAA to AAA in HBV-related cirrhotic patients. The goal of the current study is to investigate the effect of a carbohydrate-containing late-evening snack on plasma amino acid profiles in adults with hepatitis B-related cirrhosis.


## 2. Subjects and Methods

### 2.1. Subjects

86 inpatients (68 males and 18 females, mean age:51.47±11.78 years) with HBV-related cirrhosis and eighty inpatients (42 males and 38 females, mean age: 38.33±10.16 years) with chronic hepatitis B were included in the study (2017 March–2019 March). A total of 30 healthy controls were obtained from the staff of the Department, during the same period. The diagnosis is hepatitis B viral infection according to serology results (COBAS AmpliPrep/COBAS TaqMan HBV test, Roche Molecular Systems Inc, Branchburg, NJ, USA). HBV-related chronic hepatitis and cirrhosis definitions referred to the guidelines of prevention and treatment for chronic hepatitis B (2015). Inclusion criteria include all HBV-related cirrhosis and chronic hepatitis B patients hospitalized in our department, aged between 18 and 65 years. Patients were excluded from the study if they had a known history of hepatitis C virus infection, alcoholic liver disease, severe infection, malignant tumor such as liver cancer, active gastrointestinal bleeding within 2 weeks, intravenous or oral amino acid or protein preparations within 2 weeks, diabetes mellitus, and thyroid dysfunction or were infected with human immunodeficiency virus. The study complies with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Human Research Committee of Capital Medical University. All participants signed written informed consent prior to study enrollment.


### 2.2. Study Design

Eighty-six consecutive patients with HBV-related cirrhosis were classified into three groups based on the Child-Pugh grades; 28 patients were considered Child’s grade A, 28 patients were grade B, and 30 patients were grade C. Eighty consecutive patients with chronic hepatitis B were selected as the chronic hepatitis B group. Thirty subjects were recruited as the healthy control. The blood samples were collected to analyze the laboratory values (hematologic, biochemical) and the amino acid profiles by the automatic amino acid analyzer (membraPure GmbH, Berlin, GER) on the first morning after admission.According to random numbers generated in advance, all the 86 cirrhotic patients were randomly divided into two groups, the study group (with LES supplementation;n=43) and the control group (n=43). The patients with the study group received the nutritional intervention of 200 kcal late-evening snacks for six months; the patients in the control group were not supplemented with the LES. The blood samples were collected to examine the laboratory values (hematologic, biochemical) and the amino acid profiles before and 1, 3, and 6 months after LES intervention, respectively. All patients received standard antiviral treatment (entecavir 0.5 mg/day; Squibb Pharmaceuticals Ltd., Shanghai, China). All patients’ dietary intake was required to be recorded weekly. And energy and nutrient intake were evaluated through referring to the collected food intake records. To minimize the difference in energy and macronutrient intake between both groups, two full-time staffs were responsible for the follow-up of both groups and provided weekly telephone diet guidance. Seven patients were lost to follow-up, with four in the study group and three in the control group. No adverse reactions were observed in either group.


### 2.3. Testing of Plasma Amino Acid Profiles

Venous blood was drawn from each patient after overnight fasting. Plasma was centrifuged at a speed of 2000 r/min at normal atmospheric temperature for 5 min. Plasma was separated and stored in a refrigerator at -80°C for reserve. Amino acid analysis was performed at the Beijing Institute of Hepatology using the A300 Amino Acid Analyzer (membraPure GmbH, Berlin, GER). Twenty amino acid concentrations in total were measured. These include essential amino acids (histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, and valine) that cannot be synthesized by humans, nonessential amino acids (glutamic acid, alanine, glycine, aspartate, cystine, proline, serine, and tyrosine), branched chain amino acids (leucine, isoleucine, and valine) which are critical to muscle metabolism, aromatic amino acids (tyrosine, phenylalanine, and tryptophan), and sulfur amino acids (cysteine and methionine) which are critical for redox metabolism, among other functions.


### 2.4. LES Snack

Patients in the study group were given an LES in the form of lotus-root starch, which is a traditional snack in China. Traditionally, lotus-root starch is usually used as a thickening agent in sauces in mixed food dishes and/or served as a constituent in pudding making. The nutritional composition of the LES includes 200 kcal energy in total, 50 g of carbohydrate, 0.1 g protein, and 0.05 g fiber with a GI of 30 [14, 15].


### 2.5. Laboratory Parameters

Biochemical parameters including cholesterol, triglyceride, aspartate aminotransferase, alanine aminotransferase, prealbumin, albumin, creatinine, total bilirubin, and cholinesterase were measured using a chemistry analyzer (Olympus 5421, Olympus, Tokyo, Japan). The automatic coagulation analyzer (TOP700, ACL, American) was applied to analyze prothrombin time (PT) and international normalized ratio (INR). The automated hematology analyzer (XE-5000 analyzer, Hissen Meikang, Kōbe, Japan) was used to evaluate levels of white blood cells, hemoglobin, and platelets.


### 2.6. Statistical Analysis

SPSS 19.0 statistical software (SPSS Inc., Chicago, IL, USA) was used for data analysis. All data were analyzed for normality and were described as themean±s.d. Baseline characteristics between groups were compared using one-way ANOVA, independent group t-test, and χ2 test. The effects of LES were evaluated by repeated measures analysis of variance. P<0.05 was considered statistically significant.


## 2.1. Subjects

86 inpatients (68 males and 18 females, mean age:51.47±11.78 years) with HBV-related cirrhosis and eighty inpatients (42 males and 38 females, mean age: 38.33±10.16 years) with chronic hepatitis B were included in the study (2017 March–2019 March). A total of 30 healthy controls were obtained from the staff of the Department, during the same period. The diagnosis is hepatitis B viral infection according to serology results (COBAS AmpliPrep/COBAS TaqMan HBV test, Roche Molecular Systems Inc, Branchburg, NJ, USA). HBV-related chronic hepatitis and cirrhosis definitions referred to the guidelines of prevention and treatment for chronic hepatitis B (2015). Inclusion criteria include all HBV-related cirrhosis and chronic hepatitis B patients hospitalized in our department, aged between 18 and 65 years. Patients were excluded from the study if they had a known history of hepatitis C virus infection, alcoholic liver disease, severe infection, malignant tumor such as liver cancer, active gastrointestinal bleeding within 2 weeks, intravenous or oral amino acid or protein preparations within 2 weeks, diabetes mellitus, and thyroid dysfunction or were infected with human immunodeficiency virus. The study complies with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Human Research Committee of Capital Medical University. All participants signed written informed consent prior to study enrollment.


## 2.2. Study Design

Eighty-six consecutive patients with HBV-related cirrhosis were classified into three groups based on the Child-Pugh grades; 28 patients were considered Child’s grade A, 28 patients were grade B, and 30 patients were grade C. Eighty consecutive patients with chronic hepatitis B were selected as the chronic hepatitis B group. Thirty subjects were recruited as the healthy control. The blood samples were collected to analyze the laboratory values (hematologic, biochemical) and the amino acid profiles by the automatic amino acid analyzer (membraPure GmbH, Berlin, GER) on the first morning after admission.According to random numbers generated in advance, all the 86 cirrhotic patients were randomly divided into two groups, the study group (with LES supplementation;n=43) and the control group (n=43). The patients with the study group received the nutritional intervention of 200 kcal late-evening snacks for six months; the patients in the control group were not supplemented with the LES. The blood samples were collected to examine the laboratory values (hematologic, biochemical) and the amino acid profiles before and 1, 3, and 6 months after LES intervention, respectively. All patients received standard antiviral treatment (entecavir 0.5 mg/day; Squibb Pharmaceuticals Ltd., Shanghai, China). All patients’ dietary intake was required to be recorded weekly. And energy and nutrient intake were evaluated through referring to the collected food intake records. To minimize the difference in energy and macronutrient intake between both groups, two full-time staffs were responsible for the follow-up of both groups and provided weekly telephone diet guidance. Seven patients were lost to follow-up, with four in the study group and three in the control group. No adverse reactions were observed in either group.


## 2.3. Testing of Plasma Amino Acid Profiles

Venous blood was drawn from each patient after overnight fasting. Plasma was centrifuged at a speed of 2000 r/min at normal atmospheric temperature for 5 min. Plasma was separated and stored in a refrigerator at -80°C for reserve. Amino acid analysis was performed at the Beijing Institute of Hepatology using the A300 Amino Acid Analyzer (membraPure GmbH, Berlin, GER). Twenty amino acid concentrations in total were measured. These include essential amino acids (histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, and valine) that cannot be synthesized by humans, nonessential amino acids (glutamic acid, alanine, glycine, aspartate, cystine, proline, serine, and tyrosine), branched chain amino acids (leucine, isoleucine, and valine) which are critical to muscle metabolism, aromatic amino acids (tyrosine, phenylalanine, and tryptophan), and sulfur amino acids (cysteine and methionine) which are critical for redox metabolism, among other functions.


## 2.4. LES Snack

Patients in the study group were given an LES in the form of lotus-root starch, which is a traditional snack in China. Traditionally, lotus-root starch is usually used as a thickening agent in sauces in mixed food dishes and/or served as a constituent in pudding making. The nutritional composition of the LES includes 200 kcal energy in total, 50 g of carbohydrate, 0.1 g protein, and 0.05 g fiber with a GI of 30 [14, 15].


## 2.5. Laboratory Parameters

Biochemical parameters including cholesterol, triglyceride, aspartate aminotransferase, alanine aminotransferase, prealbumin, albumin, creatinine, total bilirubin, and cholinesterase were measured using a chemistry analyzer (Olympus 5421, Olympus, Tokyo, Japan). The automatic coagulation analyzer (TOP700, ACL, American) was applied to analyze prothrombin time (PT) and international normalized ratio (INR). The automated hematology analyzer (XE-5000 analyzer, Hissen Meikang, Kōbe, Japan) was used to evaluate levels of white blood cells, hemoglobin, and platelets.


## 2.6. Statistical Analysis

SPSS 19.0 statistical software (SPSS Inc., Chicago, IL, USA) was used for data analysis. All data were analyzed for normality and were described as themean±s.d. Baseline characteristics between groups were compared using one-way ANOVA, independent group t-test, and χ2 test. The effects of LES were evaluated by repeated measures analysis of variance. P<0.05 was considered statistically significant.


## 3. Results

### 3.1. Basic Characteristics of Research Objects

Demographic characteristics (age and gender) and laboratory values (hematologic, biochemical) were compared between the cirrhosis group, the chronic hepatitis B group, and the healthy control group. The mean age of patients in the chronic hepatitis B group was significantly lower than the mean age of patients in the other two groups (P<0.01, respectively). The difference in gender was not statistically significant. The level of white blood cells, hemoglobin, platelets, albumin, prealbumin, and cholinesterase in patients with cirrhosis was significantly lower than those in patients with chronic hepatitis B and healthy controls (P<0.01, respectively), and the level of aspartate transferase, total bilirubin, prothrombin time, and INR was significantly higher than those in the chronic hepatitis B group and the healthy control group (P<0.01, respectively). These three groups demonstrated no significant difference in alanine aminotransferase, creatinine, and triglyceride (Table 1).Table 1
Basic characteristics of patients with cirrhosis and chronic hepatitis B (X¯±s.d.).
Cirrhosis groupChronic hepatitis B groupHealthy control groupFPN868030—Age51.5±11.539.9±6.6∗47.7±8.213.81<0.001Gender (M/F)68/1810/87/3—0.108WBC (×109/L)5.1±1.77.5±1.7∗7.6±1.7∗21.38<0.001HB (g/L)107.1±22.6120.8±10.3∗127.9±4.3∗34.44<0.001PLT (×109/L)65.7±21.0173.5±39.3∗253.2±48.2∗284.22<0.001ALT (U/L)45.6±19.339.2±8.735.6±7.22.200.116AST (U/L)74.8±30.026.6±8.0∗26.3±6.1∗35.35<0.001TBIL (μmol/L)48.0±23.416.3±4.2∗14.8±3.3∗26.01<0.001ALB (g/L)28.6±4.441.4±3.3∗41.7±3.0∗100.86<0.001PALB (mg/L)95.4±27.0199.8±23.2∗181.9±22.1∗150.11<0.001CHE (U/L)3925.7±1241.28113.6±656.8∗9938.1±1531.5∗179.72<0.001CR (μmol/L)61.3±16.756.5±11.549.5±10.0∗2.970.056CHOL (mmol/L)4.3±0.84.1±0.54.6±0.91.040.356TG (mmol/L)1.4±0.71.2±0.41.1±0.42.550.083PT (s)16.7±2.313.5±1.0∗13.3±0.8∗25.52<0.001INR1.3±0.21.2±0.1∗1.1±0.1∗10.10<0.001NH3 (μmol/L)79.6±27.544.3±17.1∗27.2±11.6∗52.38<0.001GLU (mmol/L)5.1±2.36.2±2.35.9±2.61.1750.279Abbreviations: WBC: white blood cell count; HB: hemoglobin; PLT: platelet count; ALT: alanine aminotransferase; AST: aspartate transferase; TBIL: total bilirubin; ALB: albumin; PALB: prealbumin; CHE: cholinesterase; CR: creatinine; CHOL: total cholesterol; TG: triglyceride; PT: prothrombin time; INR: international normalized ratio; NH3: ammonemia; GLU: blood glucose; BCAA: branched chain amino acids; AAA: aromatic amino acids. ∗P<0.01 compared with the cirrhosis group.


### 3.2. Characteristics of Plasma Amino Acid Profiles in Patients with Chronic Hepatitis and Cirrhosis

Compared with the healthy control group, the concentrations of taurine, aspartic acid, threonine, serine, glycine, glutamine, cysteine, tyrosine, phenylalanine, arginine, and methionine in the cirrhosis group were significantly increased, while the concentrations of glutamic acid, valine, leucine, and the BCAA/AAA ratio were significantly decreased; the concentration of aspartic acid, threonine, serine, valine, and phenylalanine in the chronic hepatitis B group increased, the concentrations of leucine decreased, and the difference was statistically significant. No significant differences were found with respect to the concentration of other amino acids between the healthy control group and the cirrhosis group and the chronic hepatitis B group. Compared with the chronic hepatitis B group, the concentration of aspartic acid, glutamic acid, valine, and leucine and the ratio of BCAA to AAA in the cirrhosis group were significantly decreased, while the concentration of cysteine, tyrosine, phenylalanine, arginine, and methionine was increased, and the differences were statistically significant. No significant difference was detected in the concentration of other amino acids between the chronic hepatitis B group and the cirrhosis group (Table2).Table 2
Comparison of plasma amino acid profiles between cirrhosis group, chronic hepatitis B group, and healthy control group (X¯±s.d.).
Amino acid (μmol/L)Cirrhosis groupn=86Chronic hepatitis B groupn=80Healthy control groupn=30FPTAU428.4±283.3388.0±37.7197.5±48.9∗3.890.023ASP16.7±11.428.5±16.4∗∗12.9±8.7∗∗10.00<0.001THR165.6±66.9178.0±40.4117.6±19.1∗∗3.400.037SER161.8±6.96152.3±66.595.8±25.7∗∗4.400.014GLU38.2±12.850.9±13.7∗∗50.3±15.7∗∗9.44<0.001GLY279.4±105.0246.5±170.0184.3±67.2∗3.340.038ALA401.4±156.7397.1±175.1441.7±189.20.2960.744GLN847.1±78.8733.3±101.7683.5±98.2∗2.490.046CYS106.2±21.858.1±11.3∗63.7±10.1∗57.64<0.001VAL204.1±94.2285.0±84.0∗∗213.3±61.65.970.003ILE92.9±31.2102.7±31.7101.6±31.00.930.396LEU135.1±32.9157.5±37.8∗∗184.0±18.5∗18.74<0.001TYR142.4±37.182.5±22.6∗∗58.0±22.4∗∗44.21<0.001PHE88.3±18.262.7±11.1∗∗45.2±11.9∗∗42.26<0.001HIS72.6±15.872.1±16.368.0±13.50.370.688TRP52.4±19.644.7±9.342.8±6.72.400.096ORN435.8±83.3439.8±104.4477.4±96.31.000.371LYS215.1±55.1204.3±45.3180.8±35.82.060.132ARG88.1±23.276.5±15.5∗72.2±16.5∗4.050.020PRO189.5±42.6186.6±41.1194.3±34.70.110.897MET27.3±5.418.9±4.7∗∗21.5±5.1∗∗7.250.007BCAA/AAA1.59±0.522.98±0.62∗3.41±0.68∗83.91<0.001Abbreviations: TAU: taurine; ASP: aspartic acid; THR: threonine; SER: serine; GLU: glutamic acid; GLY: glycine; ALA: alanine; GLN: glutamine; CYS: cysteine; VAL: valine; LEU: leucine; ILE: isoleucinetyrosine; TYR: tyrosine; PHE: phenylalanine; HIS: histidine; TRP: tryptophan; ORN: ornithine; LYS: lysine; ARG: arginine; PRO: proline; MET: methionine.∗P<0.05 compared with cirrhosis group; ∗∗P<0.01 compared with cirrhosis group.


### 3.3. Characteristics of Plasma Amino Acid Profiles in Cirrhosis Patients with Hyperammonemia and Normal Ammonemia

According to the level of ammonia, sixty-four patients with Child-Pugh class B and C cirrhosis were divided into two groups: hyperammonemia group and normal ammonemia group. Compared with the normal ammonemia group, the concentrations of taurine, glycine, glutamine, tyrosine, tryptophan, and arginine in the hyperammonemia group were increased, while the concentrations of aspartic acid, leucine, and isoleucinetyrosine and the ratio of BCAA to AAA were decreased, and the difference was statistically significant (Table3).Table 3
Comparison of plasma amino acid profiles in cirrhosis patients with hyperammonemia and normal ammonemia (X¯±s.d.).
Amino acid (μmol/L)Patients with normal ammonemian=28Patients with hyperammonemian=36tPTAU317.9±181.3706.5±242.547.63<0.001ASP22.6±13.38.4±3.518.01<0.001THR167.5±102.5154.0±39.10.810.449SER158.2±90.1141.3±65.23.390.038GLU39.1±11.038.3±13.00.150.864GLY233.5±77.9300.0±140.04.280.017ALA373.9±103.8384.0±166.21.890.158GLN701.3±88.6889.3±75.93.180.047CYS101.2±26.4110.4±17.61.310.277VAL221.4±100.6190.9±90.60.780.462ILE105.5±40.085.8±25.03.550.033LEU149.2±29.9122.8±29.15.160.008TYR130.9±31.4158.3±33.14.770.011PHE83.6±17.692.7±17.41.920.154HIS70.1±15.874.4±16.20.540.586TRP40.6±10.561.8±19.710.68<0.001ORN418.8±85.4443.2±89.60.860.425LYS217.1±40.4204.7±54.40.940.396ARG79.0±19.993.6±21.43.510.034PRO196.0±46.5186.7±41.60.470.625MET25.8±6.230.9±4.62.580.059BCAA/AAA1.94±0.581.31±0.3414.33<0.001Abbreviations: TAU: taurine; ASP: aspartic acid; THR: threonine; SER: serine; GLU: glutamic acid; GLY: glycine; ALA: alanine; GLN: glutamine; CYS: cysteine; VAL: valine; LEU: leucine; ILE: isoleucinetyrosine; TYR: tyrosine; PHE: phenylalanine; HIS: histidine; TRP: tryptophan; ORN: ornithine; LYS: lysine; ARG: arginine; PRO: proline; MET: methionine; BCAA: branched chain amino acids; AAA: aromatic amino acids.


### 3.4. Effect of Late-Evening Snacks on Biochemical Parameters and Plasma Amino Acid Profiles in Patients with Liver Cirrhosis

#### 3.4.1. Basic Characteristics and Macronutrient Intake of the Study and Control Groups

The basic characteristics of the two groups are shown in Table4. No significant difference was found in age, gender, anthropometry data, and laboratory values between the study and control groups (P>0.05). Macronutrient intake of the two groups at baseline and 3rd month and 6th month is shown in Table 4. These two groups demonstrated no significant difference in macronutrient intake.Table 4
Basic characteristics of study and control group (X¯±s.d.).
Study groupControl grouptPN4343——Age51.0±10.350.2±11.70.2510.803Gender (M/F)19/722/4—0.202Height (cm)171.5±8.1170.8±7.20.4960.627Weight (kg)69.8±12.568.2±13.70.1120.955BMI23.8±3.823.3±4.00.1730.867Macronutrient intake at baselineCarbohydrate (g/day)247.6±42.4246.3±46.90.9740.381Fat (g/day)41.4±14.242.7±14.70.1360.883Protein (g/day)68.9±12.969.3±13.10.1320.886Energy (kcal/day)1652.1±251.71649.0±267.50.1750.862Macronutrient intake after 3 monthsCarbohydrate (g/day)250.6±49.0248.1±48.20.9780.379Fat (g/day)40.3±13.841.5±14.00.1400.879Protein (g/day)70.1±9.569.6±12.50.1360.884Energy (kcal/day)1644.6±257.71643.2±252.90.1810.858Macronutrient intake after 6 monthsCarbohydrate (g/day)251.0±42.7250.3±47.10.9770.380Fat (g/day)42.1±12.940.2±13.60.1510.876Protein (g/day)69.4±13.271.2±14.70.1470.877Energy (kcal/day)1655.5±248.81653.8±258.10.1640.869


#### 3.4.2. Laboratory Values

Changes of laboratory values in patients with cirrhosis before and after late-evening snacks are shown in Table5. No significant differences in laboratory values at baseline were observed between the study group and the control group (P<0.05). Compared with baseline, the levels of ALB and PALB in the study group were significantly increased, while the level of NH3 was significantly decreased both at the 3rd month and the 6th month (P<0.05).Table 5
Changes of laboratory values in patients with cirrhosis before and after late-evening snacks (X¯±s.d.).
Study groupControl groupTreatment effectsBaseline (n=43)1st month (n=43)3rd month (n=41)6th month (n=39)FPBaseline (n=43)1st month (n=43)3rd month (n=42)6th month (n=40)FPPWBC (×109/L)4.2±1.84.3±1.94.5±1.85.0±1.71.4490.2424.8±1.84.6±1.94.2±1.94.2±1.71.0760.3460.108HB (g/L)89.9±24.290.3±27.494.8±24.8101.5±29.71.2340.29790.9±21.493.5±25.897.0±22.892.0±22.40.5340.5890.218PLT (×109/L)84.4±16.883.1±22.080.1±32.279.5±20.10.3160.73078.4±25.680.6±24.087.1±14.180.0±19.01.4870.2330.924ALT (U/L)54.6±20.353.8±21.649.8±17.346.3±18.01.2790.28456.2±17.154.7±18.951.3±18.650.5±20.00.6980.5010.447AST (U/L)65.0±28.166.9±24.768.2±21.666.6±19.10.1240.88376.6±32.174.3±30.663.8±18.270.6±17.91.7770.1770.448TBIL (μmol/L)44.0±15.245.5±18.144.6±18.239.8±17.10.5910.55640.1±12.841.4±17.244.5±16.142.8±18.00.4870.6170.564ALB (g/L)29.8±4.032.0±3.231.8±5.733.8±4.2∗4.6140.01329.4±5.729.9±6.030.0±5.830.8±5.50.3860.6810.036PALB (mg/L)105.9±25.1110.4±28.7122.3±30.5∗126.9±30.2∗3.7790.027102.9±23.4108.2±21.7107.8±25.4106.8±33.00.2290.7960.031CHE (U/L)4524.3±1275.84324.3±1319.64332.7±1471.44459.3±1414.80.1180.8894399.9±1416.74310.9±1428.24159.3±1425.74310.3±1471.10.1770.8380.730CR (μmol/L)60.0±17.261.7±18.262.1±15.060.5±18.70.1050.90160.8±18.452.4±15.558.3±14.358.4±14.80.1990.8200.663CHOL (mmol/L)4.4±0.84.5±0.94.8±1.14.6±1.11.0850.3434.5±0.94.8±0.85.0±1.04.9±1.01.6430.2010.501TG (mmol/L)1.7±0.71.8±0.81.9±0.61.7±0.60.7760.4641.6±0.81.7±0.91.8±0.71.9±0.61.1610.3190.281PT (S)15.3±1.715.1±1.915.1±1.815.0±1.40.1860.83115.2±1.615.9±1.915.1±1.514.3±1.52.1450.1250.100INR1.2±0.31.2±0.41.2±0.21.3±0.10.1780.8371.2±0.11.3±0.21.3±0.11.2±0.20.1850.1640.458NH3 (μmol/L)68.6±25.666.1±27.455.5±22.5∗47.6±20.7∗2.4670.03165.4±24.762.7±26.157.4±20.260.6±21.21.0890.3450.045GLU (mmol/L)5.1±2.35.5±2.96.0±2.35.5±2.60.3420.6935.8±3.15.9±3.85.2±3.96.0±1.70.2170.7280.469Abbreviations: WBC: white blood cell count; HB: hemoglobin; PLT: platelet count; ALT: alanine aminotransferase; AST: aspartate transferase; TBIL: total bilirubin; ALB: albumin; PALB: prealbumin; CHE: cholinesterase; CR: creatinine; CHOL: total cholesterol; TG: triglyceride; PT: prothrombin time; INR: international normalized ratio; NH3: ammonemia; GLU: blood glucose. ∗P<0.05 compared with baseline.The potential impact of LES supplementation on ALB, PALB, and NH3 was explored through dividing the treatment group (+LES) into three groups based on the Child-Pugh grade with the Child-Pugh A group (n=11), the Child-Pugh B group (n=12), and the Child-Pugh C group (n=20). In spite of the obvious difference in the levels of ALB, PALB, and NH3 in the Child-Pugh A group after 6 months of LES supplementation, LES treatment contributed to a significant increase in levels of ALB and PALB and a significant decrease in NH3 in patients with Child-Pugh B and C at the 6th month (Table 6).Table 6
Changes of ALB, PALB, and NH3 before and after late-evening snacks in patients with cirrhosis of different Child-Pugh grades (X¯±s.d.).
Baseline1st month3rd month6th monthFPChild-Pugh A (n=11)ALB (g/L)33.5±4.734.3±3.835.1±4.135.8±4.41.0820.348PALB (mg/L)128.8±26.9126.2±27.4130.0±28.1132.1±28.40.1310.832NH3 (μmol/L)39.6±24.833.8±24.432.4±23.032.1±22.70.3580.672Child-Pugh B (n=12)ALB (g/L)29.1±4.432.7±5.133.5±3.934.2±4.63.7420.015PALB (mg/L)106.4±29.1112.3±28.4125.6±27.3127.4±26.63.7820.026NH3 (μmol/L)68.0±25.660.1±25.455.5±22.147.6±23.32.1180.044Child-Pugh C (n=20)ALB (g/L)24.2±4.827.0±4.230.0±3.932.4±5.05.7820.006PALB (mg/L)87.7±25.8102.3±26.7116.3±27.7120.7±28.05.4380.007NH3 (μmol/L)91.1±24.888.7±24.078.3±25.260.5±25.83.7840.023Abbreviations: ALB: albumin; PALB: prealbumin; NH3: ammonemia.


#### 3.4.3. Plasma Amino Acid Profiles

No significant differences in plasma amino acid concentration at baseline were noted between the study and control groups (P<0.05). Compared with baseline, the concentration of leucine and isoleucine and the ratio of BCAA to AAA in the study group increased gradually at the 1st month, 3rd month, and 6th month, and significant statistical differences were observed at the 6th month (P<0.05). In the meantime, the concentration of threonine and tryptophan in the study group decreased gradually, the lowest concentration of which was observed at the 6th month (P<0.05). Meanwhile, there are no significant differences in plasma amino acid concentration at the 6th month compared with baseline in the control group (P<0.05). However, comparing with the control group, a significant increase in VAL (P<0.05) and BCAA/AAA ratio (P<0.01) and an obvious decrease in MET (P<0.01) were observed in patients in the study group after 6 months of LES supplementation (Table 7).Table 7
Changes of plasma amino acid profiles in patients with cirrhosis before and after late-evening snacks (X¯±s.d.).
Amino acid (μmol/L)Study groupControl groupTreatment effectsBaseline (n=43)1st month (n=43)3rd month (n=41)6th month (n=39)FPBaseline (n=43)6th month (n=40)tPPTAU296.6±147.0255.8±103.2270.9±112.0288.8±110.70.6050.613315.7±145.7309.1±118.20.1760.8610.537ASP20.7±12.719.7±6.619.8±7.020.8±7.70.1050.95719.3±8.822.7±11.51.1820.2430.497THR172.8±25.0157.0±68.3165.3±63.8133.1±57.9∗2.3680.075181.5±32.1159.5±57.51.6830.0990.115SER157.0±93.5183.9±59.4181.8±63.0162.5±67.20.9080.440162.3±41.7167.3±41.80.3660.7160.783GLU38.9±11.437.7±12.939.9±12.536.2±11.00.4760.70038.0±14.741.9±12.01.0150.3150.081GLY235.4±80.1252.8±90.9251.9±93.0270.1±96.50.6280.599250.9±67.2275.0±76.81.1840.2420.844ALA377.1±106.7387.5±130.8420.8±135.1372.6±135.10.7220.541372.5±159.7396.1±128.80.5720.5700.545GLN808.3±107.5797.4±92.1789.1±128.3766.6±120.91.0380.375812.6±147.4802.7±115.00.1980.8560.369CYS100.3±27.1109.0±24.2102.8±21.997.2±18.61.2050.312106.9±20.2104.5±24.80.3680.7140.246VAL228.1±101.0205.7±92.1215.0±94.0258.1±66.21.6470.183211.0±94.1210.8±82.60.0080.9940.032ILE92.8±27.898.8±35.6107.5±33.8112.2±33.6∗1.7480.15595.4±24.498.6±34.00.3900.6980.167LEU141.8±28.1145.3±42.9161.2±36.7164.3±37.8∗2.3820.074145.2±34.0139.4±61.30.4240.6730.092TYR131.1±31.5123.2±45.8132.5±46.7126.4±35.70.2870.834139.2±41.8132.2±47.30.5530.5830.631PHE84.6±17.980.6±32.081.0±30.475.7±24.10.4720.70389.5±19.880.4±29.21.2910.2030.542HIS70.8±15.868.1±20.271.5±15.972.3.7±19.10.2680.84871.0±17.970.3±16.10.1440.8860.701TRP46.5±14.046.4±19.445.5±16.437.1±16.0∗1.8940.13646.2±18.046.3±16.80.0100.9920.057ORN418.8±85.6459.0±117.6475.5±104.4431.8±107.11.5460.208445.7±77.0403.2±136.01.3730.1760.416LYS215.6±41.6226.9±58.2218.7±56.7223.1±61.20.2110.889221.1±69.1226.0±63.80.2640.7930.872ARG85.8±23.782.9±23.786.5±25.880.4±24.40.3390.79784.5±25.385.8±25.00.1930.8480.445PRO193.5±46.7192.9±58.7181.3±44.0174.9±45.40.8730.458188.7±40.2179.3±40.60.8230.4150.721MET24.9±7.924.4±6.723.1±8.121.2±6.81.2230.30523.4±7.026.5±6.51.6210.1120.008BCAA/AAA1.81±0.501.95±0.852.05±0.632.32±0.60∗∗2.8190.0431.77±0.431.80±0.611.8070.4240.003Abbreviations: TAU: taurine; ASP: aspartic acid; THR: threonine; SER: serine; GLU: glutamic acid; GLY: glycine; ALA: alanine; GLN: glutamine; CYS: cysteine; VAL: valine; LEU: leucine; ILE: isoleucinetyrosine; TYR: tyrosine; PHE: phenylalanine; HIS: histidine; TRP: tryptophan; ORN: ornithine; LYS: lysine; ARG: arginine; PRO: proline; MET: methionine. BCAA: branched chain amino acids; AAA: aromatic amino acids.∗P<0.05 compared with baseline; ∗∗P<0.01 compared with baseline.Compared with baseline, LES treatment at the 6th month resulted in a significantly higher increase in the ratio of BCAA/AAA in patients with Child-Pugh B (1.86 vs. 2.38;P=0.027) and C (1.72 vs. 2.18; P=0.046), while the impact of LES supplementation was not obvious in the Child-Pugh A group (2.03 vs. 2.39; P=0.268) (Figure 1).Figure 1
The impact of disease severity on the ratio of BCAA to AAA in cirrhosis patients due to hepatitis B infection supplemented with a late-evening snack. Notes: compared with baseline, for LES treatment at 6th month, the ratio of BCAA to AAA in patients with Child-Pugh B and C increased; the difference was statistically significant, while the impact of LES supplementation was not obvious in Child-Pugh A group. BCAA: branched chain amino acids; AAA: aromatic amino acids.


## 3.1. Basic Characteristics of Research Objects

Demographic characteristics (age and gender) and laboratory values (hematologic, biochemical) were compared between the cirrhosis group, the chronic hepatitis B group, and the healthy control group. The mean age of patients in the chronic hepatitis B group was significantly lower than the mean age of patients in the other two groups (P<0.01, respectively). The difference in gender was not statistically significant. The level of white blood cells, hemoglobin, platelets, albumin, prealbumin, and cholinesterase in patients with cirrhosis was significantly lower than those in patients with chronic hepatitis B and healthy controls (P<0.01, respectively), and the level of aspartate transferase, total bilirubin, prothrombin time, and INR was significantly higher than those in the chronic hepatitis B group and the healthy control group (P<0.01, respectively). These three groups demonstrated no significant difference in alanine aminotransferase, creatinine, and triglyceride (Table 1).Table 1
Basic characteristics of patients with cirrhosis and chronic hepatitis B (X¯±s.d.).
Cirrhosis groupChronic hepatitis B groupHealthy control groupFPN868030—Age51.5±11.539.9±6.6∗47.7±8.213.81<0.001Gender (M/F)68/1810/87/3—0.108WBC (×109/L)5.1±1.77.5±1.7∗7.6±1.7∗21.38<0.001HB (g/L)107.1±22.6120.8±10.3∗127.9±4.3∗34.44<0.001PLT (×109/L)65.7±21.0173.5±39.3∗253.2±48.2∗284.22<0.001ALT (U/L)45.6±19.339.2±8.735.6±7.22.200.116AST (U/L)74.8±30.026.6±8.0∗26.3±6.1∗35.35<0.001TBIL (μmol/L)48.0±23.416.3±4.2∗14.8±3.3∗26.01<0.001ALB (g/L)28.6±4.441.4±3.3∗41.7±3.0∗100.86<0.001PALB (mg/L)95.4±27.0199.8±23.2∗181.9±22.1∗150.11<0.001CHE (U/L)3925.7±1241.28113.6±656.8∗9938.1±1531.5∗179.72<0.001CR (μmol/L)61.3±16.756.5±11.549.5±10.0∗2.970.056CHOL (mmol/L)4.3±0.84.1±0.54.6±0.91.040.356TG (mmol/L)1.4±0.71.2±0.41.1±0.42.550.083PT (s)16.7±2.313.5±1.0∗13.3±0.8∗25.52<0.001INR1.3±0.21.2±0.1∗1.1±0.1∗10.10<0.001NH3 (μmol/L)79.6±27.544.3±17.1∗27.2±11.6∗52.38<0.001GLU (mmol/L)5.1±2.36.2±2.35.9±2.61.1750.279Abbreviations: WBC: white blood cell count; HB: hemoglobin; PLT: platelet count; ALT: alanine aminotransferase; AST: aspartate transferase; TBIL: total bilirubin; ALB: albumin; PALB: prealbumin; CHE: cholinesterase; CR: creatinine; CHOL: total cholesterol; TG: triglyceride; PT: prothrombin time; INR: international normalized ratio; NH3: ammonemia; GLU: blood glucose; BCAA: branched chain amino acids; AAA: aromatic amino acids. ∗P<0.01 compared with the cirrhosis group.


## 3.2. Characteristics of Plasma Amino Acid Profiles in Patients with Chronic Hepatitis and Cirrhosis

Compared with the healthy control group, the concentrations of taurine, aspartic acid, threonine, serine, glycine, glutamine, cysteine, tyrosine, phenylalanine, arginine, and methionine in the cirrhosis group were significantly increased, while the concentrations of glutamic acid, valine, leucine, and the BCAA/AAA ratio were significantly decreased; the concentration of aspartic acid, threonine, serine, valine, and phenylalanine in the chronic hepatitis B group increased, the concentrations of leucine decreased, and the difference was statistically significant. No significant differences were found with respect to the concentration of other amino acids between the healthy control group and the cirrhosis group and the chronic hepatitis B group. Compared with the chronic hepatitis B group, the concentration of aspartic acid, glutamic acid, valine, and leucine and the ratio of BCAA to AAA in the cirrhosis group were significantly decreased, while the concentration of cysteine, tyrosine, phenylalanine, arginine, and methionine was increased, and the differences were statistically significant. No significant difference was detected in the concentration of other amino acids between the chronic hepatitis B group and the cirrhosis group (Table2).Table 2
Comparison of plasma amino acid profiles between cirrhosis group, chronic hepatitis B group, and healthy control group (X¯±s.d.).
Amino acid (μmol/L)Cirrhosis groupn=86Chronic hepatitis B groupn=80Healthy control groupn=30FPTAU428.4±283.3388.0±37.7197.5±48.9∗3.890.023ASP16.7±11.428.5±16.4∗∗12.9±8.7∗∗10.00<0.001THR165.6±66.9178.0±40.4117.6±19.1∗∗3.400.037SER161.8±6.96152.3±66.595.8±25.7∗∗4.400.014GLU38.2±12.850.9±13.7∗∗50.3±15.7∗∗9.44<0.001GLY279.4±105.0246.5±170.0184.3±67.2∗3.340.038ALA401.4±156.7397.1±175.1441.7±189.20.2960.744GLN847.1±78.8733.3±101.7683.5±98.2∗2.490.046CYS106.2±21.858.1±11.3∗63.7±10.1∗57.64<0.001VAL204.1±94.2285.0±84.0∗∗213.3±61.65.970.003ILE92.9±31.2102.7±31.7101.6±31.00.930.396LEU135.1±32.9157.5±37.8∗∗184.0±18.5∗18.74<0.001TYR142.4±37.182.5±22.6∗∗58.0±22.4∗∗44.21<0.001PHE88.3±18.262.7±11.1∗∗45.2±11.9∗∗42.26<0.001HIS72.6±15.872.1±16.368.0±13.50.370.688TRP52.4±19.644.7±9.342.8±6.72.400.096ORN435.8±83.3439.8±104.4477.4±96.31.000.371LYS215.1±55.1204.3±45.3180.8±35.82.060.132ARG88.1±23.276.5±15.5∗72.2±16.5∗4.050.020PRO189.5±42.6186.6±41.1194.3±34.70.110.897MET27.3±5.418.9±4.7∗∗21.5±5.1∗∗7.250.007BCAA/AAA1.59±0.522.98±0.62∗3.41±0.68∗83.91<0.001Abbreviations: TAU: taurine; ASP: aspartic acid; THR: threonine; SER: serine; GLU: glutamic acid; GLY: glycine; ALA: alanine; GLN: glutamine; CYS: cysteine; VAL: valine; LEU: leucine; ILE: isoleucinetyrosine; TYR: tyrosine; PHE: phenylalanine; HIS: histidine; TRP: tryptophan; ORN: ornithine; LYS: lysine; ARG: arginine; PRO: proline; MET: methionine.∗P<0.05 compared with cirrhosis group; ∗∗P<0.01 compared with cirrhosis group.


## 3.3. Characteristics of Plasma Amino Acid Profiles in Cirrhosis Patients with Hyperammonemia and Normal Ammonemia

According to the level of ammonia, sixty-four patients with Child-Pugh class B and C cirrhosis were divided into two groups: hyperammonemia group and normal ammonemia group. Compared with the normal ammonemia group, the concentrations of taurine, glycine, glutamine, tyrosine, tryptophan, and arginine in the hyperammonemia group were increased, while the concentrations of aspartic acid, leucine, and isoleucinetyrosine and the ratio of BCAA to AAA were decreased, and the difference was statistically significant (Table3).Table 3
Comparison of plasma amino acid profiles in cirrhosis patients with hyperammonemia and normal ammonemia (X¯±s.d.).
Amino acid (μmol/L)Patients with normal ammonemian=28Patients with hyperammonemian=36tPTAU317.9±181.3706.5±242.547.63<0.001ASP22.6±13.38.4±3.518.01<0.001THR167.5±102.5154.0±39.10.810.449SER158.2±90.1141.3±65.23.390.038GLU39.1±11.038.3±13.00.150.864GLY233.5±77.9300.0±140.04.280.017ALA373.9±103.8384.0±166.21.890.158GLN701.3±88.6889.3±75.93.180.047CYS101.2±26.4110.4±17.61.310.277VAL221.4±100.6190.9±90.60.780.462ILE105.5±40.085.8±25.03.550.033LEU149.2±29.9122.8±29.15.160.008TYR130.9±31.4158.3±33.14.770.011PHE83.6±17.692.7±17.41.920.154HIS70.1±15.874.4±16.20.540.586TRP40.6±10.561.8±19.710.68<0.001ORN418.8±85.4443.2±89.60.860.425LYS217.1±40.4204.7±54.40.940.396ARG79.0±19.993.6±21.43.510.034PRO196.0±46.5186.7±41.60.470.625MET25.8±6.230.9±4.62.580.059BCAA/AAA1.94±0.581.31±0.3414.33<0.001Abbreviations: TAU: taurine; ASP: aspartic acid; THR: threonine; SER: serine; GLU: glutamic acid; GLY: glycine; ALA: alanine; GLN: glutamine; CYS: cysteine; VAL: valine; LEU: leucine; ILE: isoleucinetyrosine; TYR: tyrosine; PHE: phenylalanine; HIS: histidine; TRP: tryptophan; ORN: ornithine; LYS: lysine; ARG: arginine; PRO: proline; MET: methionine; BCAA: branched chain amino acids; AAA: aromatic amino acids.


## 3.4. Effect of Late-Evening Snacks on Biochemical Parameters and Plasma Amino Acid Profiles in Patients with Liver Cirrhosis

### 3.4.1. Basic Characteristics and Macronutrient Intake of the Study and Control Groups

The basic characteristics of the two groups are shown in Table4. No significant difference was found in age, gender, anthropometry data, and laboratory values between the study and control groups (P>0.05). Macronutrient intake of the two groups at baseline and 3rd month and 6th month is shown in Table 4. These two groups demonstrated no significant difference in macronutrient intake.Table 4
Basic characteristics of study and control group (X¯±s.d.).
Study groupControl grouptPN4343——Age51.0±10.350.2±11.70.2510.803Gender (M/F)19/722/4—0.202Height (cm)171.5±8.1170.8±7.20.4960.627Weight (kg)69.8±12.568.2±13.70.1120.955BMI23.8±3.823.3±4.00.1730.867Macronutrient intake at baselineCarbohydrate (g/day)247.6±42.4246.3±46.90.9740.381Fat (g/day)41.4±14.242.7±14.70.1360.883Protein (g/day)68.9±12.969.3±13.10.1320.886Energy (kcal/day)1652.1±251.71649.0±267.50.1750.862Macronutrient intake after 3 monthsCarbohydrate (g/day)250.6±49.0248.1±48.20.9780.379Fat (g/day)40.3±13.841.5±14.00.1400.879Protein (g/day)70.1±9.569.6±12.50.1360.884Energy (kcal/day)1644.6±257.71643.2±252.90.1810.858Macronutrient intake after 6 monthsCarbohydrate (g/day)251.0±42.7250.3±47.10.9770.380Fat (g/day)42.1±12.940.2±13.60.1510.876Protein (g/day)69.4±13.271.2±14.70.1470.877Energy (kcal/day)1655.5±248.81653.8±258.10.1640.869


### 3.4.2. Laboratory Values

Changes of laboratory values in patients with cirrhosis before and after late-evening snacks are shown in Table5. No significant differences in laboratory values at baseline were observed between the study group and the control group (P<0.05). Compared with baseline, the levels of ALB and PALB in the study group were significantly increased, while the level of NH3 was significantly decreased both at the 3rd month and the 6th month (P<0.05).Table 5
Changes of laboratory values in patients with cirrhosis before and after late-evening snacks (X¯±s.d.).
Study groupControl groupTreatment effectsBaseline (n=43)1st month (n=43)3rd month (n=41)6th month (n=39)FPBaseline (n=43)1st month (n=43)3rd month (n=42)6th month (n=40)FPPWBC (×109/L)4.2±1.84.3±1.94.5±1.85.0±1.71.4490.2424.8±1.84.6±1.94.2±1.94.2±1.71.0760.3460.108HB (g/L)89.9±24.290.3±27.494.8±24.8101.5±29.71.2340.29790.9±21.493.5±25.897.0±22.892.0±22.40.5340.5890.218PLT (×109/L)84.4±16.883.1±22.080.1±32.279.5±20.10.3160.73078.4±25.680.6±24.087.1±14.180.0±19.01.4870.2330.924ALT (U/L)54.6±20.353.8±21.649.8±17.346.3±18.01.2790.28456.2±17.154.7±18.951.3±18.650.5±20.00.6980.5010.447AST (U/L)65.0±28.166.9±24.768.2±21.666.6±19.10.1240.88376.6±32.174.3±30.663.8±18.270.6±17.91.7770.1770.448TBIL (μmol/L)44.0±15.245.5±18.144.6±18.239.8±17.10.5910.55640.1±12.841.4±17.244.5±16.142.8±18.00.4870.6170.564ALB (g/L)29.8±4.032.0±3.231.8±5.733.8±4.2∗4.6140.01329.4±5.729.9±6.030.0±5.830.8±5.50.3860.6810.036PALB (mg/L)105.9±25.1110.4±28.7122.3±30.5∗126.9±30.2∗3.7790.027102.9±23.4108.2±21.7107.8±25.4106.8±33.00.2290.7960.031CHE (U/L)4524.3±1275.84324.3±1319.64332.7±1471.44459.3±1414.80.1180.8894399.9±1416.74310.9±1428.24159.3±1425.74310.3±1471.10.1770.8380.730CR (μmol/L)60.0±17.261.7±18.262.1±15.060.5±18.70.1050.90160.8±18.452.4±15.558.3±14.358.4±14.80.1990.8200.663CHOL (mmol/L)4.4±0.84.5±0.94.8±1.14.6±1.11.0850.3434.5±0.94.8±0.85.0±1.04.9±1.01.6430.2010.501TG (mmol/L)1.7±0.71.8±0.81.9±0.61.7±0.60.7760.4641.6±0.81.7±0.91.8±0.71.9±0.61.1610.3190.281PT (S)15.3±1.715.1±1.915.1±1.815.0±1.40.1860.83115.2±1.615.9±1.915.1±1.514.3±1.52.1450.1250.100INR1.2±0.31.2±0.41.2±0.21.3±0.10.1780.8371.2±0.11.3±0.21.3±0.11.2±0.20.1850.1640.458NH3 (μmol/L)68.6±25.666.1±27.455.5±22.5∗47.6±20.7∗2.4670.03165.4±24.762.7±26.157.4±20.260.6±21.21.0890.3450.045GLU (mmol/L)5.1±2.35.5±2.96.0±2.35.5±2.60.3420.6935.8±3.15.9±3.85.2±3.96.0±1.70.2170.7280.469Abbreviations: WBC: white blood cell count; HB: hemoglobin; PLT: platelet count; ALT: alanine aminotransferase; AST: aspartate transferase; TBIL: total bilirubin; ALB: albumin; PALB: prealbumin; CHE: cholinesterase; CR: creatinine; CHOL: total cholesterol; TG: triglyceride; PT: prothrombin time; INR: international normalized ratio; NH3: ammonemia; GLU: blood glucose. ∗P<0.05 compared with baseline.The potential impact of LES supplementation on ALB, PALB, and NH3 was explored through dividing the treatment group (+LES) into three groups based on the Child-Pugh grade with the Child-Pugh A group (n=11), the Child-Pugh B group (n=12), and the Child-Pugh C group (n=20). In spite of the obvious difference in the levels of ALB, PALB, and NH3 in the Child-Pugh A group after 6 months of LES supplementation, LES treatment contributed to a significant increase in levels of ALB and PALB and a significant decrease in NH3 in patients with Child-Pugh B and C at the 6th month (Table 6).Table 6
Changes of ALB, PALB, and NH3 before and after late-evening snacks in patients with cirrhosis of different Child-Pugh grades (X¯±s.d.).
Baseline1st month3rd month6th monthFPChild-Pugh A (n=11)ALB (g/L)33.5±4.734.3±3.835.1±4.135.8±4.41.0820.348PALB (mg/L)128.8±26.9126.2±27.4130.0±28.1132.1±28.40.1310.832NH3 (μmol/L)39.6±24.833.8±24.432.4±23.032.1±22.70.3580.672Child-Pugh B (n=12)ALB (g/L)29.1±4.432.7±5.133.5±3.934.2±4.63.7420.015PALB (mg/L)106.4±29.1112.3±28.4125.6±27.3127.4±26.63.7820.026NH3 (μmol/L)68.0±25.660.1±25.455.5±22.147.6±23.32.1180.044Child-Pugh C (n=20)ALB (g/L)24.2±4.827.0±4.230.0±3.932.4±5.05.7820.006PALB (mg/L)87.7±25.8102.3±26.7116.3±27.7120.7±28.05.4380.007NH3 (μmol/L)91.1±24.888.7±24.078.3±25.260.5±25.83.7840.023Abbreviations: ALB: albumin; PALB: prealbumin; NH3: ammonemia.


### 3.4.3. Plasma Amino Acid Profiles

No significant differences in plasma amino acid concentration at baseline were noted between the study and control groups (P<0.05). Compared with baseline, the concentration of leucine and isoleucine and the ratio of BCAA to AAA in the study group increased gradually at the 1st month, 3rd month, and 6th month, and significant statistical differences were observed at the 6th month (P<0.05). In the meantime, the concentration of threonine and tryptophan in the study group decreased gradually, the lowest concentration of which was observed at the 6th month (P<0.05). Meanwhile, there are no significant differences in plasma amino acid concentration at the 6th month compared with baseline in the control group (P<0.05). However, comparing with the control group, a significant increase in VAL (P<0.05) and BCAA/AAA ratio (P<0.01) and an obvious decrease in MET (P<0.01) were observed in patients in the study group after 6 months of LES supplementation (Table 7).Table 7
Changes of plasma amino acid profiles in patients with cirrhosis before and after late-evening snacks (X¯±s.d.).
Amino acid (μmol/L)Study groupControl groupTreatment effectsBaseline (n=43)1st month (n=43)3rd month (n=41)6th month (n=39)FPBaseline (n=43)6th month (n=40)tPPTAU296.6±147.0255.8±103.2270.9±112.0288.8±110.70.6050.613315.7±145.7309.1±118.20.1760.8610.537ASP20.7±12.719.7±6.619.8±7.020.8±7.70.1050.95719.3±8.822.7±11.51.1820.2430.497THR172.8±25.0157.0±68.3165.3±63.8133.1±57.9∗2.3680.075181.5±32.1159.5±57.51.6830.0990.115SER157.0±93.5183.9±59.4181.8±63.0162.5±67.20.9080.440162.3±41.7167.3±41.80.3660.7160.783GLU38.9±11.437.7±12.939.9±12.536.2±11.00.4760.70038.0±14.741.9±12.01.0150.3150.081GLY235.4±80.1252.8±90.9251.9±93.0270.1±96.50.6280.599250.9±67.2275.0±76.81.1840.2420.844ALA377.1±106.7387.5±130.8420.8±135.1372.6±135.10.7220.541372.5±159.7396.1±128.80.5720.5700.545GLN808.3±107.5797.4±92.1789.1±128.3766.6±120.91.0380.375812.6±147.4802.7±115.00.1980.8560.369CYS100.3±27.1109.0±24.2102.8±21.997.2±18.61.2050.312106.9±20.2104.5±24.80.3680.7140.246VAL228.1±101.0205.7±92.1215.0±94.0258.1±66.21.6470.183211.0±94.1210.8±82.60.0080.9940.032ILE92.8±27.898.8±35.6107.5±33.8112.2±33.6∗1.7480.15595.4±24.498.6±34.00.3900.6980.167LEU141.8±28.1145.3±42.9161.2±36.7164.3±37.8∗2.3820.074145.2±34.0139.4±61.30.4240.6730.092TYR131.1±31.5123.2±45.8132.5±46.7126.4±35.70.2870.834139.2±41.8132.2±47.30.5530.5830.631PHE84.6±17.980.6±32.081.0±30.475.7±24.10.4720.70389.5±19.880.4±29.21.2910.2030.542HIS70.8±15.868.1±20.271.5±15.972.3.7±19.10.2680.84871.0±17.970.3±16.10.1440.8860.701TRP46.5±14.046.4±19.445.5±16.437.1±16.0∗1.8940.13646.2±18.046.3±16.80.0100.9920.057ORN418.8±85.6459.0±117.6475.5±104.4431.8±107.11.5460.208445.7±77.0403.2±136.01.3730.1760.416LYS215.6±41.6226.9±58.2218.7±56.7223.1±61.20.2110.889221.1±69.1226.0±63.80.2640.7930.872ARG85.8±23.782.9±23.786.5±25.880.4±24.40.3390.79784.5±25.385.8±25.00.1930.8480.445PRO193.5±46.7192.9±58.7181.3±44.0174.9±45.40.8730.458188.7±40.2179.3±40.60.8230.4150.721MET24.9±7.924.4±6.723.1±8.121.2±6.81.2230.30523.4±7.026.5±6.51.6210.1120.008BCAA/AAA1.81±0.501.95±0.852.05±0.632.32±0.60∗∗2.8190.0431.77±0.431.80±0.611.8070.4240.003Abbreviations: TAU: taurine; ASP: aspartic acid; THR: threonine; SER: serine; GLU: glutamic acid; GLY: glycine; ALA: alanine; GLN: glutamine; CYS: cysteine; VAL: valine; LEU: leucine; ILE: isoleucinetyrosine; TYR: tyrosine; PHE: phenylalanine; HIS: histidine; TRP: tryptophan; ORN: ornithine; LYS: lysine; ARG: arginine; PRO: proline; MET: methionine. BCAA: branched chain amino acids; AAA: aromatic amino acids.∗P<0.05 compared with baseline; ∗∗P<0.01 compared with baseline.Compared with baseline, LES treatment at the 6th month resulted in a significantly higher increase in the ratio of BCAA/AAA in patients with Child-Pugh B (1.86 vs. 2.38;P=0.027) and C (1.72 vs. 2.18; P=0.046), while the impact of LES supplementation was not obvious in the Child-Pugh A group (2.03 vs. 2.39; P=0.268) (Figure 1).Figure 1
The impact of disease severity on the ratio of BCAA to AAA in cirrhosis patients due to hepatitis B infection supplemented with a late-evening snack. Notes: compared with baseline, for LES treatment at 6th month, the ratio of BCAA to AAA in patients with Child-Pugh B and C increased; the difference was statistically significant, while the impact of LES supplementation was not obvious in Child-Pugh A group. BCAA: branched chain amino acids; AAA: aromatic amino acids.


## 3.4.1. Basic Characteristics and Macronutrient Intake of the Study and Control Groups

The basic characteristics of the two groups are shown in Table4. No significant difference was found in age, gender, anthropometry data, and laboratory values between the study and control groups (P>0.05). Macronutrient intake of the two groups at baseline and 3rd month and 6th month is shown in Table 4. These two groups demonstrated no significant difference in macronutrient intake.Table 4
Basic characteristics of study and control group (X¯±s.d.).
Study groupControl grouptPN4343——Age51.0±10.350.2±11.70.2510.803Gender (M/F)19/722/4—0.202Height (cm)171.5±8.1170.8±7.20.4960.627Weight (kg)69.8±12.568.2±13.70.1120.955BMI23.8±3.823.3±4.00.1730.867Macronutrient intake at baselineCarbohydrate (g/day)247.6±42.4246.3±46.90.9740.381Fat (g/day)41.4±14.242.7±14.70.1360.883Protein (g/day)68.9±12.969.3±13.10.1320.886Energy (kcal/day)1652.1±251.71649.0±267.50.1750.862Macronutrient intake after 3 monthsCarbohydrate (g/day)250.6±49.0248.1±48.20.9780.379Fat (g/day)40.3±13.841.5±14.00.1400.879Protein (g/day)70.1±9.569.6±12.50.1360.884Energy (kcal/day)1644.6±257.71643.2±252.90.1810.858Macronutrient intake after 6 monthsCarbohydrate (g/day)251.0±42.7250.3±47.10.9770.380Fat (g/day)42.1±12.940.2±13.60.1510.876Protein (g/day)69.4±13.271.2±14.70.1470.877Energy (kcal/day)1655.5±248.81653.8±258.10.1640.869


## 3.4.2. Laboratory Values

Changes of laboratory values in patients with cirrhosis before and after late-evening snacks are shown in Table5. No significant differences in laboratory values at baseline were observed between the study group and the control group (P<0.05). Compared with baseline, the levels of ALB and PALB in the study group were significantly increased, while the level of NH3 was significantly decreased both at the 3rd month and the 6th month (P<0.05).Table 5
Changes of laboratory values in patients with cirrhosis before and after late-evening snacks (X¯±s.d.).
Study groupControl groupTreatment effectsBaseline (n=43)1st month (n=43)3rd month (n=41)6th month (n=39)FPBaseline (n=43)1st month (n=43)3rd month (n=42)6th month (n=40)FPPWBC (×109/L)4.2±1.84.3±1.94.5±1.85.0±1.71.4490.2424.8±1.84.6±1.94.2±1.94.2±1.71.0760.3460.108HB (g/L)89.9±24.290.3±27.494.8±24.8101.5±29.71.2340.29790.9±21.493.5±25.897.0±22.892.0±22.40.5340.5890.218PLT (×109/L)84.4±16.883.1±22.080.1±32.279.5±20.10.3160.73078.4±25.680.6±24.087.1±14.180.0±19.01.4870.2330.924ALT (U/L)54.6±20.353.8±21.649.8±17.346.3±18.01.2790.28456.2±17.154.7±18.951.3±18.650.5±20.00.6980.5010.447AST (U/L)65.0±28.166.9±24.768.2±21.666.6±19.10.1240.88376.6±32.174.3±30.663.8±18.270.6±17.91.7770.1770.448TBIL (μmol/L)44.0±15.245.5±18.144.6±18.239.8±17.10.5910.55640.1±12.841.4±17.244.5±16.142.8±18.00.4870.6170.564ALB (g/L)29.8±4.032.0±3.231.8±5.733.8±4.2∗4.6140.01329.4±5.729.9±6.030.0±5.830.8±5.50.3860.6810.036PALB (mg/L)105.9±25.1110.4±28.7122.3±30.5∗126.9±30.2∗3.7790.027102.9±23.4108.2±21.7107.8±25.4106.8±33.00.2290.7960.031CHE (U/L)4524.3±1275.84324.3±1319.64332.7±1471.44459.3±1414.80.1180.8894399.9±1416.74310.9±1428.24159.3±1425.74310.3±1471.10.1770.8380.730CR (μmol/L)60.0±17.261.7±18.262.1±15.060.5±18.70.1050.90160.8±18.452.4±15.558.3±14.358.4±14.80.1990.8200.663CHOL (mmol/L)4.4±0.84.5±0.94.8±1.14.6±1.11.0850.3434.5±0.94.8±0.85.0±1.04.9±1.01.6430.2010.501TG (mmol/L)1.7±0.71.8±0.81.9±0.61.7±0.60.7760.4641.6±0.81.7±0.91.8±0.71.9±0.61.1610.3190.281PT (S)15.3±1.715.1±1.915.1±1.815.0±1.40.1860.83115.2±1.615.9±1.915.1±1.514.3±1.52.1450.1250.100INR1.2±0.31.2±0.41.2±0.21.3±0.10.1780.8371.2±0.11.3±0.21.3±0.11.2±0.20.1850.1640.458NH3 (μmol/L)68.6±25.666.1±27.455.5±22.5∗47.6±20.7∗2.4670.03165.4±24.762.7±26.157.4±20.260.6±21.21.0890.3450.045GLU (mmol/L)5.1±2.35.5±2.96.0±2.35.5±2.60.3420.6935.8±3.15.9±3.85.2±3.96.0±1.70.2170.7280.469Abbreviations: WBC: white blood cell count; HB: hemoglobin; PLT: platelet count; ALT: alanine aminotransferase; AST: aspartate transferase; TBIL: total bilirubin; ALB: albumin; PALB: prealbumin; CHE: cholinesterase; CR: creatinine; CHOL: total cholesterol; TG: triglyceride; PT: prothrombin time; INR: international normalized ratio; NH3: ammonemia; GLU: blood glucose. ∗P<0.05 compared with baseline.The potential impact of LES supplementation on ALB, PALB, and NH3 was explored through dividing the treatment group (+LES) into three groups based on the Child-Pugh grade with the Child-Pugh A group (n=11), the Child-Pugh B group (n=12), and the Child-Pugh C group (n=20). In spite of the obvious difference in the levels of ALB, PALB, and NH3 in the Child-Pugh A group after 6 months of LES supplementation, LES treatment contributed to a significant increase in levels of ALB and PALB and a significant decrease in NH3 in patients with Child-Pugh B and C at the 6th month (Table 6).Table 6
Changes of ALB, PALB, and NH3 before and after late-evening snacks in patients with cirrhosis of different Child-Pugh grades (X¯±s.d.).
Baseline1st month3rd month6th monthFPChild-Pugh A (n=11)ALB (g/L)33.5±4.734.3±3.835.1±4.135.8±4.41.0820.348PALB (mg/L)128.8±26.9126.2±27.4130.0±28.1132.1±28.40.1310.832NH3 (μmol/L)39.6±24.833.8±24.432.4±23.032.1±22.70.3580.672Child-Pugh B (n=12)ALB (g/L)29.1±4.432.7±5.133.5±3.934.2±4.63.7420.015PALB (mg/L)106.4±29.1112.3±28.4125.6±27.3127.4±26.63.7820.026NH3 (μmol/L)68.0±25.660.1±25.455.5±22.147.6±23.32.1180.044Child-Pugh C (n=20)ALB (g/L)24.2±4.827.0±4.230.0±3.932.4±5.05.7820.006PALB (mg/L)87.7±25.8102.3±26.7116.3±27.7120.7±28.05.4380.007NH3 (μmol/L)91.1±24.888.7±24.078.3±25.260.5±25.83.7840.023Abbreviations: ALB: albumin; PALB: prealbumin; NH3: ammonemia.


## 3.4.3. Plasma Amino Acid Profiles

No significant differences in plasma amino acid concentration at baseline were noted between the study and control groups (P<0.05). Compared with baseline, the concentration of leucine and isoleucine and the ratio of BCAA to AAA in the study group increased gradually at the 1st month, 3rd month, and 6th month, and significant statistical differences were observed at the 6th month (P<0.05). In the meantime, the concentration of threonine and tryptophan in the study group decreased gradually, the lowest concentration of which was observed at the 6th month (P<0.05). Meanwhile, there are no significant differences in plasma amino acid concentration at the 6th month compared with baseline in the control group (P<0.05). However, comparing with the control group, a significant increase in VAL (P<0.05) and BCAA/AAA ratio (P<0.01) and an obvious decrease in MET (P<0.01) were observed in patients in the study group after 6 months of LES supplementation (Table 7).Table 7
Changes of plasma amino acid profiles in patients with cirrhosis before and after late-evening snacks (X¯±s.d.).
Amino acid (μmol/L)Study groupControl groupTreatment effectsBaseline (n=43)1st month (n=43)3rd month (n=41)6th month (n=39)FPBaseline (n=43)6th month (n=40)tPPTAU296.6±147.0255.8±103.2270.9±112.0288.8±110.70.6050.613315.7±145.7309.1±118.20.1760.8610.537ASP20.7±12.719.7±6.619.8±7.020.8±7.70.1050.95719.3±8.822.7±11.51.1820.2430.497THR172.8±25.0157.0±68.3165.3±63.8133.1±57.9∗2.3680.075181.5±32.1159.5±57.51.6830.0990.115SER157.0±93.5183.9±59.4181.8±63.0162.5±67.20.9080.440162.3±41.7167.3±41.80.3660.7160.783GLU38.9±11.437.7±12.939.9±12.536.2±11.00.4760.70038.0±14.741.9±12.01.0150.3150.081GLY235.4±80.1252.8±90.9251.9±93.0270.1±96.50.6280.599250.9±67.2275.0±76.81.1840.2420.844ALA377.1±106.7387.5±130.8420.8±135.1372.6±135.10.7220.541372.5±159.7396.1±128.80.5720.5700.545GLN808.3±107.5797.4±92.1789.1±128.3766.6±120.91.0380.375812.6±147.4802.7±115.00.1980.8560.369CYS100.3±27.1109.0±24.2102.8±21.997.2±18.61.2050.312106.9±20.2104.5±24.80.3680.7140.246VAL228.1±101.0205.7±92.1215.0±94.0258.1±66.21.6470.183211.0±94.1210.8±82.60.0080.9940.032ILE92.8±27.898.8±35.6107.5±33.8112.2±33.6∗1.7480.15595.4±24.498.6±34.00.3900.6980.167LEU141.8±28.1145.3±42.9161.2±36.7164.3±37.8∗2.3820.074145.2±34.0139.4±61.30.4240.6730.092TYR131.1±31.5123.2±45.8132.5±46.7126.4±35.70.2870.834139.2±41.8132.2±47.30.5530.5830.631PHE84.6±17.980.6±32.081.0±30.475.7±24.10.4720.70389.5±19.880.4±29.21.2910.2030.542HIS70.8±15.868.1±20.271.5±15.972.3.7±19.10.2680.84871.0±17.970.3±16.10.1440.8860.701TRP46.5±14.046.4±19.445.5±16.437.1±16.0∗1.8940.13646.2±18.046.3±16.80.0100.9920.057ORN418.8±85.6459.0±117.6475.5±104.4431.8±107.11.5460.208445.7±77.0403.2±136.01.3730.1760.416LYS215.6±41.6226.9±58.2218.7±56.7223.1±61.20.2110.889221.1±69.1226.0±63.80.2640.7930.872ARG85.8±23.782.9±23.786.5±25.880.4±24.40.3390.79784.5±25.385.8±25.00.1930.8480.445PRO193.5±46.7192.9±58.7181.3±44.0174.9±45.40.8730.458188.7±40.2179.3±40.60.8230.4150.721MET24.9±7.924.4±6.723.1±8.121.2±6.81.2230.30523.4±7.026.5±6.51.6210.1120.008BCAA/AAA1.81±0.501.95±0.852.05±0.632.32±0.60∗∗2.8190.0431.77±0.431.80±0.611.8070.4240.003Abbreviations: TAU: taurine; ASP: aspartic acid; THR: threonine; SER: serine; GLU: glutamic acid; GLY: glycine; ALA: alanine; GLN: glutamine; CYS: cysteine; VAL: valine; LEU: leucine; ILE: isoleucinetyrosine; TYR: tyrosine; PHE: phenylalanine; HIS: histidine; TRP: tryptophan; ORN: ornithine; LYS: lysine; ARG: arginine; PRO: proline; MET: methionine. BCAA: branched chain amino acids; AAA: aromatic amino acids.∗P<0.05 compared with baseline; ∗∗P<0.01 compared with baseline.Compared with baseline, LES treatment at the 6th month resulted in a significantly higher increase in the ratio of BCAA/AAA in patients with Child-Pugh B (1.86 vs. 2.38;P=0.027) and C (1.72 vs. 2.18; P=0.046), while the impact of LES supplementation was not obvious in the Child-Pugh A group (2.03 vs. 2.39; P=0.268) (Figure 1).Figure 1
The impact of disease severity on the ratio of BCAA to AAA in cirrhosis patients due to hepatitis B infection supplemented with a late-evening snack. Notes: compared with baseline, for LES treatment at 6th month, the ratio of BCAA to AAA in patients with Child-Pugh B and C increased; the difference was statistically significant, while the impact of LES supplementation was not obvious in Child-Pugh A group. BCAA: branched chain amino acids; AAA: aromatic amino acids.


## 4. Discussion

Our discovery showed that there was a significant amino acid imbalance in patients with chronic hepatitis, especially in patients with cirrhosis, which was manifested by the decreased level of branched chain amino acid, the increased level of aromatic amino acid level, and the decrease of BCAA to AAA ratio. Daily consumption of carbohydrate-predominant late-evening snacks for 6 months significantly increased the ratio of BCAA to AAA and improved the imbalance of amino acids in patients with hepatitis B-related cirrhosis, especially for those with Child-Pugh B and C stages.In this study, we compared the concentrations of plasma amino acid in patients with cirrhosis and chronic hepatitis B and healthy subjects. The plasma levels of branched chain amino acids (leucine, valine, and isoleucine) in patients with cirrhosis and chronic hepatitis B were significantly lower than those in the healthy control group, while the level of glutamine was significantly higher in patients with cirrhosis and chronic hepatitis B. Recently, increasing studies have shown that hyperammonemia and hyperglutaminemia could exert an effect on the reduction of branched chain amino acids. Current studies suggest that intestinal bacteria are not the major source of ammonia in cirrhosis patients, but intestinal catabolism of glutamine in blood [16, 17]. It has been proved that the close relationship between glutamine and ammonia metabolism plays a central role in the pathogenesis of hyperammonemia, hyperglutaminemia, and BCAA reduction in patients with liver cirrhosis [18]. Our study also confirmed that patients with hyperammonemia have higher glutamine levels. Another characteristic of plasma amino acid profiles in patients with chronic hepatitis and cirrhosis is elevated levels of aromatic amino acids. Plasma levels of AAA increase partially due to the deficient function in liver detoxification, portal-systemic shunting, and increased protein catabolism [19]. In addition to the changes of branched chain amino acids and aromatic amino acids, our study also showed that the plasma concentration of taurine, aspartic acid, threonine, serine, glycine, glutamine, cysteine, arginine, and methionine in patients with cirrhosis or chronic hepatitis B was significantly higher than that in healthy control groups. These phenomenons may be related to many factors, such as decreased protein synthesis, metabolic dysfunction, and increased muscle decomposition in patients with liver disease.Convergent evidence suggested that nutritional supplementation is an effective vehicle to improve overall nutritional status in patients with cirrhosis [20]. Most of these studies have focused on BCAA supplementation, which exerts beneficial effect on the nutritional status and substrate utilization in adults with liver disease [12, 21]. However, gastrointestinal upset resulting from BCAA supplementation limits patients’ long-term adherence to BCAA supplementation, which to some extent challenged the research with a long time of follow-up. Our previous study found that a carbohydrate-predominant late-evening snack is responsible for the increase in fasting carbohydrate oxidation, resting energy expenditure (REE), and reductions in fat oxidation in adults with chronic liver disease [13]. The use of a carbohydrate-based (low glycemic index) nutritional module that is absorbed more slowly overnight promoted carbohydrate utilization for energy supplementation and decreased fat and protein mobilization from the adipocyte and lean tissue.With six-month nutritional intervention by carbohydrate-predominant late-evening snack, we can observe that the level of ALB and PALB in the study group significantly increased, and the level of NH3 significantly decreased. We reasoned that LES-treated patients demonstrated a significantly higher overall survival than PS-matched patients who did not receive LES therapy. More importantly, this survival benefit was more significant in patients with Child-Pugh C cirrhosis than in those with Child-Pugh A or B cirrhosis. In the 6th month, unbalanced amino acid profiles improved gradually; the ratio of BCAA to AAA increased significantly. Hepatic encephalopathy is one of the most common complications of severe liver disease. Its pathogenesis has not yet been fully elucidated. The main theories include hyperammonemia and amino acid imbalance [22, 23]. It was shown that cirrhosis patients exhibited more pronounced clearance of BCAA from plasma compared to healthy subjects [24]. Most authors believe that BCAA levels are decreased partially because of their support in muscle ammonia clearance [25]. Studies have implied that BCAA is effective in the treatment of hepatic encephalopathy complicated in cirrhosis and liver failure [26, 27]. Increased BCAA concentrations in the blood and muscles can stimulate ammonia removal from the blood and promote the recovery of muscle strength. Phenylalanine and tyrosine are not synthesized in vivo, and they are not converted into other metabolites in skeletal muscle. Proteolysis leads to an increase in plasma concentration of phenylalanine and tyrosine. Patients with cirrhosis are catabolic, and AAA release from muscle tissue may contribute to the higher AAA blood concentrations in cirrhosis patients. Our previous study found that carbohydrate-predominant LES could potentially improve the status of protein-energy malnutrition which occurs in patients with liver cirrhosis and promote the improvement of liver function [13]. These factors may result in a reduction of skeletal muscle decomposition catabolism; therefore, the release of AAA is reduced. On the other hand, recovery of liver function contributes to the degradation of ammonia and reduces the consumption of BCAA. LES not only help to improve the ratio of BCAA to AAA but also decrease the level of ammonia and glutamine and increase the level of albumin and prealbumin. The most beneficial population was patients with Child-Pugh B and C grades.This study has several limitations. The retrospective nature of our study limits the assessment of variables including dietary intake, daily physical activity or exercise, and weight change, all of which may affect outcomes in patients with chronic liver disease. Limitations in this study design include carbohydrate which is the main component of LES; for better taste, branched amino acids are not added. With the continuous research and development of functional food, the addition of special functional ingredients may be able to improve the amino acid imbalance in a shorter time. The detection method of amino acids is another limitation in this study. The method used in this study is an automatic amino acid analyzer. Currently, the more accurate detection method is high-performance liquid chromatography (HPLC). The sensitivity (minimum detection limit) of the automatic amino acid analyzer is slightly lower than that of HPLC (automatic amino acid analyzer vs. HPLC: <3 pmol vs. <0.5 pmol). But it has little influence on the results of this study. If possible, the choice of HPLC is more accurate. The advantage of this study is that most patients in the LES group were followed up effectively. Our team has enough full-time staff to follow up and conduct weekly guidance by telephone to ensure a low drop-off rate and credibility of the results. In addition, none of the patients experienced any adverse side effects. A prospective study should be performed to validate the findings of the present study. Finally, our study is based on a single-center cohort of patients, which has a potential limitation to generalize our findings to other populations and regions. Therefore, further multicenter and prospective cohort studies are warranted to clarify the causal relationship between LES and survival.In conclusion, there was significant amino acid imbalance in patients with chronic hepatitis, especially cirrhosis, which was manifested by the decreased level of branched chain amino acid and BCAA to AAA ratio and the increased level of aromatic amino acid level. The application of an LES carbohydrate module (lotus-root starch) for six months in liver cirrhosis patients was beneficial in increasing the ratio of BCAA to AAA and decreasing the level of ammonia. The most beneficial population was patients with Child-Pugh B and C grades.



---

*Source: 1074565-2021-11-22.xml*